Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off

Stopping Ozempic or Wegovy does not cause a withdrawal syndrome: neither label describes one.^[1][2] What does happen is slower and more predictable. The drug takes about five weeks to clear, appetite returns, and weight starts coming back. In a 2026 BMJ meta-analysis, people who stopped semaglutide or tirzepatide regained an average of 0.8 kg (about 1.8 lb) a month, and were projected to be back at their starting weight about a year and a half later.^[5] The best-tested way to hold on to the loss afterward is supervised exercise, built up while still on treatment, in a trial of an older GLP-1.^[9][10]

Side effects of stopping Ozempic: what the labels say

Search for side effects after stopping Ozempic and you will find stories of rebound hunger, nausea and mood swings. The prescribing information is quieter. Neither the Ozempic nor the Wegovy label has a section on symptoms caused by stopping, and neither describes withdrawal effects of the kind seen with some psychiatric or pain drugs.^[1][2] Their warnings about pancreatitis, gallbladder disease and stomach problems are about taking the drug, not about coming off it.

Part of the reason is pharmacology. Semaglutide clears slowly: its elimination half-life is roughly one week. Per the Ozempic label, the drug remains in circulation around 5 weeks past the final dose; the Wegovy label says about 5 to 7 weeks after a last 2.4 mg or 7.2 mg injection or 25 mg tablet.^[1][2] So even stopping Ozempic suddenly is not a sudden event inside the body. The level falls by roughly half each week, which is a slow fade over a month or more.

The side effects people tend to notice are therefore the drug’s effects wearing off, in both directions:

• Digestive symptoms usually ease. In the STEP 4 trial, people switched from semaglutide to placebo reported gastrointestinal events far less often than those who stayed on it: 26.1% against 49.1% over the following 48 weeks.^[4]
• Appetite comes back. Hunger and what many people call food noise return as the drug clears. This is covered in more detail below.
• Weight and the health markers that improved with it drift back. Blood pressure, blood sugar and cholesterol tend to move back toward where they started as weight returns.^[3][5]
• Blood sugar can rise if you have type 2 diabetes. Ozempic is a diabetes medicine first.^[2] Stopping it removes a glucose-lowering drug, which is a reason to talk to whoever manages your diabetes before the last pen runs out.

Why appetite and food noise come back

Most people stopping a GLP-1 describe the same first change: hunger, and constant thoughts about food, return before the scale moves much. A 2026 review of what happens after stopping lists the likely reasons: appetite signaling returns once the drug’s GLP-1 effect is gone, and hunger hormones such as ghrelin rise in response to the weight that was lost. The authors add that some of these mechanisms are still poorly proven in people.^[7]

There is a gap here. No withdrawal trial has published appetite on a validated scale as an outcome, so there is no reliable figure for how many weeks it takes. What “food noise” is, and what has been measured about it while on treatment, is in our food noise explainer.

How quickly does weight return once you stop Ozempic?

Asking whether you will gain weight after stopping Ozempic has a fairly settled answer: most people regain a large share of it. Speed is the more useful question, and the evidence now gives a reasonable picture. The figures below are group averages. Individual results in every one of these studies varied widely.

Three details from the STEP 1 extension soften the headline. First, 48.2% of people who had been on semaglutide were still at least 5% below their starting weight a year after stopping, down from 86.4% at the end of treatment.^[3] Second, those who had lost the most regained the most in absolute terms, but they still ended up with the largest net loss.^[3] Third, regain appeared to be slowing toward the end of that year. The investigators could not tell whether weight was leveling off below baseline or just approaching it.^[3] That trial also withdrew its diet and exercise program along with the drug, which is not how most people stop.

The BMJ review adds a comparison that helps explain the pattern. Across 37 studies and more than 9,300 people, weight came back faster after weight-loss drugs than after behavioral programs, by about 0.3 kg a month, even after adjusting for the amount of weight people had lost first. After a behavioral program, the projected return to baseline was about 3.9 years, against 1.7 years for drugs as a whole.^[5] The review rated the evidence on rate of regain as moderate certainty.

Outside trials, the picture is less steep, but not because the drug keeps working. In a cohort of 7,938 people who stopped semaglutide or tirzepatide in routine care, 19.6% restarted the same drug within a year and 35.2% received another obesity treatment.^[6] Why that produces a much smaller average regain is explained in what people actually do after stopping.

Why do people gain weight after stopping Ozempic?

Semaglutide treats appetite and weight while it is in the body; it does not reset them. The body also defends lost weight by burning less energy and raising hunger, a process explained in metabolic adaptation and regain. When the drug clears, nothing is holding back that pressure. The STEP 1 extension authors read their own results as evidence that obesity is a chronic condition needing ongoing treatment.^[3] Regaining weight is the expected course after stopping a chronic treatment, not a personal failure.

Stopping Ozempic cold turkey or tapering: what the evidence says

Many people want to know whether stopping Ozempic cold turkey is riskier than tapering down. The honest answer is that nobody knows yet. Neither label sets out a taper. The only dose-reduction steps in them are the escalation schedule used when starting and the missed-dose rules.^[1][2] A 2026 review concluded that whether structured tapering helps people come off these drugs is unknown and needs proper trials.^[7]

That trial has now been designed. REST, a Canadian randomized trial whose protocol was published in July 2026, will compare a 16-week gradual dose reduction with stopping at once in people who have lost at least 10% on semaglutide and stopped losing more. Its main outcome is weight change, and it will also measure blood pressure and ghrelin.^[8] No results have been published. Until they are, any taper schedule you see online is a guess. For tirzepatide, a separate trial tested stepping down to a lower maintenance dose, covered in the tirzepatide maintenance-dose trial; there is no equivalent randomized trial for semaglutide. Why a planned handover with your clinician matters is discussed in stopping as a clinical transition.

Stopping Ozempic as a woman: pregnancy, birth control and regain

Searches for Ozempic side effects in females after stopping usually come down to three things: pregnancy planning, contraception, and whether women regain differently. Here is what the sources support.

Planning a pregnancy. This is the one situation where both labels tell you to stop, and they set a lead time because of the long half-life:

Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.

— Ozempic prescribing information, section 8.3

Wegovy’s label sets the same 2-month interval and adds that losing weight brings no benefit while pregnant and could harm the fetus.^[1][2] What the labels say about pregnancy, and the limited human data, are covered in GLP-1s, pregnancy and trying to conceive.

Birth control. Neither the Ozempic nor the Wegovy label carries a contraception advisory, so stopping semaglutide does not trigger any change to a contraceptive rule.^[1][2] The four-week backup-method warning you may have read about belongs to tirzepatide (Mounjaro and Zepbound). The details are in GLP-1s and hormonal birth control.

Regain in women. In the STEP 1 extension, women on semaglutide had lost slightly more weight than men by the end of treatment, and were still slightly further below their starting weight a year after stopping.^[3] The difference was small, and no study we found reports a separate side-effect pattern for women after stopping.

How to not gain weight after stopping Ozempic: what has been tested

The best-designed trial on keeping weight off after a GLP-1 did not use semaglutide. It used liraglutide (Saxenda), an older daily drug, and it is still the most direct evidence on combining a GLP-1 with exercise and then stopping both.

In a Copenhagen trial (New England Journal of Medicine, 2021), 195 adults first lost an average of 13.1 kg on an 8-week low-calorie diet. They were then randomized to a year of supervised exercise, liraglutide, both, or placebo. Compared with placebo, the exercise group was 4.1 kg lighter at the end of the year, the liraglutide group 6.8 kg and the combination group 9.5 kg. The combination also cut body-fat percentage by about twice as much as either one alone.^[9]

The researchers then stopped all treatment and saw people again a year later. In the year off treatment, people who had been on liraglutide alone regained 6.0 kg more than people who had only exercised. Weight and body composition in the exercise group were maintained after the supervised program ended.^[10] Those who had used both kept 5.1 kg more weight off than those who had used liraglutide alone, measured from the start of the maintenance year.^[10] Only 109 of the original participants came back for that visit, so the follow-up figures are less certain than the main trial. How the same trial affected fitness and strength is covered in what exercise adds to a GLP-1.

What this does and does not show:

• Exercise is the strongest tested lever. Habits built during treatment held up after it ended in a way the drug effect did not.^[10]
• It was supervised and sustained. The exercise was a structured, moderate-to-vigorous program over a full year, not occasional walking.^[9]
• It has not been repeated with semaglutide. Semaglutide produces larger losses than liraglutide, and the BMJ review found that bigger losses tend to come with faster regain.^[5] The direction probably carries over, but the size has not been measured.
• Restarting is common and legitimate. In routine care, about one in five people restarted the same drug within a year of stopping.^[6] If weight is returning faster than you can manage, bring it up with your prescriber now instead of waiting.

Diet plans, protein targets and gradual tapers are often suggested to people coming off semaglutide, but none has been tested in a trial of people stopping it. That is why they are not listed above as evidence. They may still be sensible, and a clinician or dietitian can tailor them to you.